[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"frontotemporal-dementia-behavioral-variant\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:frontotemporal-dementia-behavioral-variant":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,82],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100633826","links-between-self-awareness-and-sociocognitive-processes-in-neurodegenerative-diseases-100633826",false,"NCT07531732","Links Between Self-awareness and Sociocognitive Processes in Neurodegenerative Diseases","Study of the Links Between Self-awareness and Sociocognitive Processes in Neurodegenerative Diseases in People With Frontotemporal Lobar Degeneration, Behavioral Variant and Alzheimer's Disease","SELFSOC","Inclusion Criteria:\n\n* Diagnosis of possible or probable behavioral variant frontotemporal dementia according to the Rascovsky 2011 criteria (DLFTvc group) OR\n* Diagnosis of Alzheimer's disease according to the Jack 2018 criteria, including biomarkers (MA group)\n* Mini-Mental State Examination (MMSE) ≥ 20\n* Age: 50-80 years\n* Sufficient reading and writing proficiency in French to enable completion of the study procedures, in the investigator's opinion\n\nExclusion Criteria:\n\n* Moderate to severe language disorders: Confrontation naming (DO 40 scale) ≤ 32\n* Inability to perform computerized tasks according to the investigator's opinion\n* Other neurological disorders (including epilepsy, Lewy body disease, vascular dementia)\n* Psychiatric comorbidities (bipolar disorder, schizophrenia, current major depressive episode)\n* Uncorrected visual impairment","ALL","50 Years","80 Years",{"count":21,"type":22},34,"ESTIMATED","OBSERVATIONAL","This monocentric, non-interventional study (SELFSOC) investigates the relationship between self-awareness and social cognition in patients with behavioral variant frontotemporal dementia (bvFTD) and Alzheimer's disease (AD).\n\nThe primary objective is to assess metacognitive efficiency related to social cognitive performance using a computerized facial emotion recognition task combined with confidence judgments. Metacognitive indices (including Mratio) will quantify the correspondence between subjective and objective performance.\n\nThirty-four participants (17 bvFTD, 17 AD; age 50-80; MMSE ≥20) will complete two study visits involving tasks assessing emotion recognition, theory of mind, and memory.",[26,27],"Frontotemporal Dementia, Behavioral Variant","Alzheimer Disease",[29,30,31,32,33,34],"Metacognition","Social cognition","Emotion recognition","Theory of Mind","Neuropsychology","Hypnotic suggestibility","RECRUITING","2026-04-08",{"date":38,"type":39},"2026-04-15","ACTUAL",{"date":41,"type":22},"2026-04",{"date":43,"type":22},"2027-12",{"name":45,"class":46},"Assistance Publique - Hôpitaux de Paris","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":69,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":47},"100562542","phase-2-vortioxetine-for-the-treatment-of-mood-and-cognitive-symptoms-in-frontotemporal-dementia-100562542","NCT06604520","Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia","Functional Neuroimaging to Examine Affective Symptoms and Cognition in Frontotemporal Dementia","FTD Patients\n\nInclusion Criteria:\n\n1. Male or Female\n2. Age 45 and above\n3. Diagnosis of possible or probable bvFTD based on international consensus criteria for behavioral variant FTD (FTDC)\n4. The presence of at least one of the following affective symptoms on the 12-item Neuropsychiatric Inventory: depression, anxiety, irritability, or agitation\n5. A global Clinical Dementia Rating (CDR®) plus National Alzheimer's Coordinating Center (NACC) Frontotemporal lobar degeneration (FTLD) Behavior and Language Domains global score (CDR® plus NACC FTLD) less than or equal to one\n6. Patients must be medically stable\n7. Vortioxetine treatment is clinically indicated\n8. Competent to provide informed consent\n\nExclusion Criteria:\n\n1. No history of drug or alcohol dependence within six months prior to study entry\n2. Negative toxicology screening for drugs of abuse\n3. Subject must not be pregnant or nursing\n4. No contraindications to Vortioxetine treatment\n5. No contraindications for Magnetic Resonance (MR) scanning (e.g. metal implanted in the body)\n\nHealthy Controls\n\nInclusion Criteria:\n\n1. Male or Female\n2. Age 45 and above\n3. Subjects must be medically stable\n4. Free of psychotropic medications\n5. Competent to provide informed consent\n\nExclusion Criteria:\n\n1. No current or past history of neurological or psychiatric illness or substance abuse\n2. Subject must not be pregnant or nursing\n3. Negative toxicology screening for drugs of abuse\n4. No contraindications for MR scanning (e.g. metal implanted in the body)",true,"45 Years",{"count":58,"type":22},50,"INTERVENTIONAL",[61],"PHASE2","The goal of this clinical trial is to learn if vortioxetine improves mood symptoms and cognition in patients with early-stage behavioral variant Frontotemporal Dementia (bvFTD). The main questions this study aims to answer are:\n\n1. Do individuals with mood symptoms and bvFTD have brain changes and cognitive profiles that differ compared to individuals without bvFTD?\n2. Do mood symptoms and cognition improve following treatment with vortioxetine?\n\nResearchers will also determine whether there are changes in the brain associated with vortioxetine treatment.\n\nParticipants will:\n\n* Undergo a screening visit that involves clinical assessments and laboratory tests\n* Undergo an initial brain magnetic resonance imaging (MRI) and fluorodeoxyglucose (18F) Positron Emission Tomography (FDG PET) scan before starting treatment with vortioxetine\n* Undergo memory and problem-solving tests before starting treatment with vortioxetine\n* Undergo approximately 12 weeks of treatment with vortioxetine, during which time there will be regular contact and assessments with the study psychiatrist\n* Undergo a repeat PET scan and repeat memory and problem-solving tests after 12 weeks of treatment with vortioxetine",[64,65,66,67,26,68],"Fronto-temporal Dementia","Fronto-temporal Lobar Dementia","Frontotemporal Degeneration","Frontotemporal Dementia (FTD)","Frontotemporal Dementia",[70,68,71,72],"FTD","Neuropsychiatric Symptoms","Antidepressant","2026-03-05",{"date":75,"type":39},"2026-03-09",{"date":77,"type":39},"2025-03-20",{"date":79,"type":22},"2029-09-01",{"name":81,"class":46},"Johns Hopkins University",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":55,"sex":17,"minAge":89,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":59,"phases":92,"briefSummary":94,"conditions":95,"keywords":97,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":47},"100570395","a-study-of-the-behavioral-variant-of-frontotemporal-dementia-and-bipolar-disorder-a-neuroimaging-and-epigenetics-integrated-approach-100570395","NCT06706687","A Study of the Behavioral Variant of Frontotemporal Dementia and Bipolar Disorder: a Neuroimaging and Epigenetics Integrated Approach","DISBAND","Inclusion Criteria:\n\n* byFTD group: patients of either sex; 18 years of age or older; diagnosis of behavioral variant Frontotemporal Dementia according to current diagnostic criteria; presence of a signed informed consent.\n* BD group: patients of either sex; 18 years of age or older; diagnosis of bipolar disorder according to DSM-V criteria; presence of a signed informed consent.\n* HC group: patients of either sex; 18 years of age or older; subjects who have gone through the same diagnostic process as patients under suspicion of a central nervous system and\u002For psychiatric disorder, resulting in the absence of cognitive deficits and mood disorders; presence of a signed informed consent.\n\nExclusion Criteria:\n\n* Diagnosis of Alzheimer's disease\n* Comorbidities interfering with the studied condition (e.g. other neurological diseases or history of substance or alcohol abuse)\n* Diseases with an inflammatory component (e.g. autoimmune diseases, tumors)\n* Pregnancy","18 Years",{"count":91,"type":22},210,[93],"NA","The aim of this study is to investigate the selective epigenetic modifications and their effect on brain's morphology and functionality in the frontotemporal dementia behavioral variant and bipolar disorder. The open-label, multicentric, interventional case-control study involves the analysis of 3 separate cohorts of patients, partly selected over the course of the past 10 years. More specifically, 80 behavioral variant Frontotemporal Dementia (bvFTD) patients (40, of whom 20 carry G4C2 expansion in the C9orf72 gene, are already available, while 40 will be prospectively recruited), 80 Bipolar Disorder (BD) patients (40, including 20 with early onset and 20 with late onset, are already available, while 40 will be prospectively recruited) and 50 healthy control (HC) subjects (20 of whom are already available from other previously approved studies), will be enrolled in this study.\n\nFor each participant a blood sample will be collected, processed, and studied in order analyze the expression of miRNA. Every participant will also undergo Nuclear Magnetic Resonance Imaging (NMR), Nuclear Magnetic Resonance Spectroscopy (1H-MRS), and Positron Emission Tomography (PET) and, lastly, a battery of behavioral scales to explore different cognitive domains will be administered to all participants by a team of psychologists and physicians. The overall estimated duration of the study is 36 months.",[96,26],"Bipolar Disorder",[98,99,100,101,102,103,104,105,106],"Bipolar Disorder (BD)","Frontotemporal Dementia, Behavioral Variant (bvFTD)","Epigenetics","Neuroimaging","miRNA","Nuclear Magnetic Resonance Imaging (NMR)","Nuclear Magnetic Resonance Spectroscopy (1H-MRS)","Positron Emission Tomography (PET)","Healthy controls (HC)","2024-11-22",{"date":109,"type":39},"2024-11-26",{"date":111,"type":39},"2021-05-19",{"date":113,"type":22},"2025-04",{"name":115,"class":46},"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico"]